Arcellx
Arcellx
ACLX
NASDAQ
68.51
USD
0.22%
About
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM).
The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology.
D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 345.4K |
| Three Month Average Volume | 9.4M |
| High Low | |
| Fifty-Two Week High | 75.1 USD |
| Fifty-Two Week Low | 30.88 USD |
| Fifty-Two Week High Date | 07 Mar 2024 |
| Fifty-Two Week Low Date | 27 Oct 2023 |
| Price and Volume | |
| Current Price | 68.74 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 17.64% |
| Thirteen Week Relative Price Change | 23.51% |
| Twenty-Six Week Relative Price Change | -6.44% |
| Fifty-Two Week Relative Price Change | 53.06% |
| Year-to-Date Relative Price Change | 4.59% |
| Price Change | |
| One Day Price Change | 1.87% |
| Thirteen Week Price Change | 32.19% |
| Twenty-Six Week Price Change | 2.87% |
| Five Day Price Change | -0.92% |
| Fifty-Two Week Price Change | 91.80% |
| Year-to-Date Price Change | 23.86% |
| Month-to-Date Price Change | 11.21% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 9.28422 USD |
| Book Value Per Share (Most Recent Quarter) | 9.0836 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 9.28422 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 9.0836 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.52106 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.29537 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.84334 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.47083 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.05111 USD |
| Normalized (Last Fiscal Year) | -1.47083 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.47083 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.05111 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.47083 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.05111 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 13.428 USD |
| Cash Per Share (Most Recent Quarter) | 9.6341 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.42838 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.99512 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.84223 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -25 |
| Cash Flow Revenue (Trailing Twelve Months) | -30 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -36.57% |
| Pretax Margin (Last Fiscal Year) | -63.48% |
| Pretax Margin (5 Year) | -338.78% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -81.47% |
| Operating Margin (Trailing Twelve Months) | -55.73% |
| Operating Margin (5 Year) | -359.16% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -64.08% |
| Net Profit Margin (Trailing Twelve Months) | -37.23% |
| Net Profit Margin (5 Year) | -339.38% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 87.43% |
| Tangible Book Value (5 Year) | 103.35% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 91.47% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 349.32% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 113.86% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -2.51% |
| EPS Change (Trailing Twelve Months) | 74.28% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 20 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -497,468,000 |
| Net Debt (Last Fiscal Year) | -662,734,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 33 |
| Price to Sales (Trailing Twelve Months) | 26 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 8 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 186.1M |
| Free Cash Flow (Trailing Twelve Months) | -42,875,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 8 |
| Total Debt to Equity (Most Recent Quarter) | 4 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -12.41% |
| Return on Assets (Trailing Twelve Months) | -7.94% |
| Return on Assets (5 Year) | -38.82% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -20.48% |
| Return on Equity (Trailing Twelve Months) | -13.80% |
| Return on Equity (5 Year) | -168.50% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -14.67% |
| Return on Investment (Trailing Twelve Months) | -9.68% |
| Return on Investment (5 Year) | -45.41% |